NCT05067530 Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study Status NOT_YET_RECRUITING Phase PHASE2
NCT05067283 A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) Status RECRUITING Phase PHASE1
NCT05063552 Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers Status ACTIVE_NOT_RECRUITING Phase PHASE2/PHASE3
NCT05061550 Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer Status RECRUITING Phase PHASE2
NCT05058651 Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung Status RECRUITING Phase PHASE2/PHASE3
NCT05048797 A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT05030077 Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma Status UNKNOWN Phase PHASE2
NCT05027633 Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA) Status RECRUITING Phase PHASE2
NCT05026593 A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer Status COMPLETED Phase PHASE1
NCT05020860 Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer Status RECRUITING Phase PHASE2
NCT05019716 Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma Status RECRUITING Phase PHASE1/PHASE2
NCT05017012 A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT05014815 Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer Status COMPLETED Phase PHASE2
NCT05012254 Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05010629 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05009082 Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer Status RECRUITING Phase PHASE3
NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Status COMPLETED Phase PHASE2
NCT05001880 Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma Status RECRUITING Phase PHASE2
NCT04994977 Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery Status TERMINATED Phase PHASE1